Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and others, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of its performance and prospects.

Alivus Life Sciences Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of early 2026. Despite this adjustment, the small-cap pharmaceutical and biotechnology firm continues to demonstrate solid operational metrics and a resilient market performance relative to broader indices, prompting a reassessment of its price attractiveness within a sector characterised by elevated multiples.

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 23 February 2026, providing investors with the latest insights into its performance and outlook.

Alivus Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven by improved price-to-earnings and price-to-book ratios relative to its historical averages and peer group. This change has prompted an upgrade in its Mojo Grade from Sell to Hold, reflecting a more favourable outlook amid a challenging pharmaceutical sector backdrop.

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Alivus Life Sciences Ltd has experienced a notable shift in its technical parameters, signalling a nuanced change in price momentum. While some indicators suggest mild bullishness, others remain bearish, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector.

Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a modest day gain of 1.53%, the stock’s broader technical landscape reveals a complex interplay of bullish and bearish signals, prompting a reassessment of its near-term outlook within the Pharmaceuticals & Biotechnology sector.

Alivus Life Sciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a positive shift in its growth trajectory. The company reported record-breaking revenue and profitability metrics, reflecting a turnaround from a previously flat financial trend to a robust positive momentum.

Alivus Life Sciences Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹10,551 crores, delivered a strong financial performance in Q3 FY26, posting net profit of ₹150.26 crores—a sequential increase of 15.58% and year-on-year growth of 9.71%. Despite this operational strength, the stock has faced significant headwinds, trading at ₹865.25 as of January 22, 2026, down 23.03% over the past year and currently in a mildly bearish technical trend.

Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from bearish to mildly bearish territory. Despite some bullish cues on shorter-term charts, the overall technical landscape remains cautious, reflecting the stock’s recent underperformance relative to the broader market and sector peers.

Alivus Life Sciences Ltd is rated Sell by MarketsMOJO. This rating was last updated on 14 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 20 January 2026, providing investors with the latest perspective on the company’s position.

Alivus Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing downside pressure amid a challenging market backdrop for the Pharmaceuticals & Biotechnology sector.